braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Środki przeciwnowotworowe - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
mektovi
pierre fabre medicament - binimetinib - czerniak - Środki przeciwnowotworowe - binimetinib w połączeniu z encorafenib jest wskazany do leczenia dorosłych pacjentów z niesprawne lub przerzutami czerniaka z mutacją v600 daleko brugh .
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Środki przeciwnowotworowe - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
sorafenib teva 200 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - sorafenibi tosilas - tabletki powlekane - 200 mg
sorafenib alvogen 200 mg tabletki powlekane
alvogen pharma trading europe eood - sorafenibi tosilas - tabletki powlekane - 200 mg
sorafenib sandoz 200 mg tabletki powlekane
sandoz gmbh - sorafenibi tosilas - tabletki powlekane - 200 mg
sorafenib g.l. 200 mg tabletki powlekane
g.l. pharma gmbh - sorafenibi tosilas - tabletki powlekane - 200 mg
sorafenib zentiva 200 mg tabletki powlekane
zentiva, k.s. - sorafenibi tosilas - tabletki powlekane - 200 mg
sorafenib mylan 200 mg tabletki powlekane
mylan ireland limited - sorafenibum - tabletki powlekane - 200 mg
sorafenib pharmascience 200 mg tabletki powlekane
pharmascience international limited - sorafenibum - tabletki powlekane - 200 mg